KRN 5500

Drug Profile

KRN 5500

Alternative Names: KRN5500; NSC-650426; SPK-241

Latest Information Update: 04 Jul 2016

Price : $50

At a glance

  • Originator Kirin Brewery; Massachusetts General Hospital
  • Developer Midatech Pharma US
  • Class Cytostatic antibiotics; Non-opioid analgesics; Purine nucleosides
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuropathic pain; Multiple myeloma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Neuropathic pain
  • Preclinical Multiple myeloma
  • Discontinued Cancer

Most Recent Events

  • 02 Nov 2015 DARA BioSciences receives extension of patent protection for KRN 5500 through a issued formulation patent in USA
  • 02 Nov 2015 KRN 5500 is still available for licensing in USA
  • 21 Aug 2015 KRN 5500 is still in phase II development for Neuropathic pain in USA and Puerto Rico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top